Cite
MLA Citation
J. Gligorov et al.. “5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial.” Breast, vol. 56, n.d., pp. S21–S22. http://access.bl.uk/ark:/81055/vdc_100123996405.0x000018